Principal Investigator Jeffrey A. Towbin, MD, co-executive director of Le Bonheur鈥檚 Heart Institute, and Kathryn Sherman, BSN, RN, clinical research coordinator, enrolled the first patient in the United States in the VALOR clinical trial.
Le Bonheur Pediatric Neurologist and Neurodevelopmental Disabilities Specialist Tanjala Gipson, MD, recently received a K23 grant from the National Institutes of Health (NIH) for her project 鈥淓arly Communication in Tuberous Sclerosis Complex (TSC) and Its Prediction of Autism.鈥�
For more than 25 years, productive collaboration between Parfenova, a basic scientist, and Pourcyrous, a clinical scientist, has centered on prevention and treatment of cerebrovascular disease that occurs due to devastating neonatal brain disorders, including epilepsy and asphyxia.
Le Bonheur鈥檚 risk-based innovation program Changing High-Risk Asthma in Memphis through Partnership (CHAMP) significantly decreased health care use related to asthma by targeting barriers to asthma care, according to research published in the Annals of Allergy, Asthma & Immunology.
